Recent from talks
Barkat Pharmaceutical Group
Knowledge base stats:
Talk channels stats:
Members stats:
Barkat Pharmaceutical Group
Barkat Pharmaceutical Group (Persian: گروه دارویی برکت, Gruh-e Darvii-ye Berekât) is an Iranian Pharmaceutical public company, which was founded in 2010, named Tadbir innovation pharmaceutical company. The company provides services through cooperation between science-based institutions and scientists based on medicine around the world. It supplies 14 percent of all the country's essential drugs through its 25 subsidiaries. The company produces 700 kinds of products in the pharmaceutical sector and offers it internally.
The Barkat Pharmaceutical Group has established as the first specialized drug and pharmaceutical research center in Iran, also it has been developed by constructing advanced pharmaceutical factories, called Barkat Pharmaceutical Town. The Barkat group complies with all common pharmaceutical standards such as the FDA, WHO, EMEA. "Cell therapy", production of "peptide medications", "research, development and processing of medicinal plants," the creation of the "Museum of Iranian-Islamic Medicine" as well as "Solids and Semi-Solids" projects are the main activities of the Group.
On 4 December 2016, the company was listed as Tehran Stock Exchange's 506th company after receiving 340 billion Rials in funding.
On 5 February 2017, 340 million shares of the Barkat Pharmaceutical Group were first Released on the Tehran Stock Exchange in the Group of Pharmaceutical Materials and Products. By this date, 50% of the company's shareholders were natural people. According to Baqerinezhad, the company's research and development deputy, 800 billion tomans is defined as investment, for the second five-year development plan of the company. Also, in order to realize the support of the private sector, a Research and Development Fund of Bold investing (VC) has been launched. It is also possible to invest over $5 billion, in full capacity, in the Barkat Pharmaceutical Town.
The Barkat Pharmaceutical Group has signed investment contracts with 30 and domestic medical and healthcare companies in the healthcare industry. So far in order to produce medicines, there are three contracts between pharmaceutical companies from Switzerland, the UK and Denmark for producing medicines. The direct investment contract of €70 million with a Danish pharmaceutical company in 2015 and a contract of $15 million with a Swiss company in 2016 were among the most important of these contracts. This holding, which has more than 500,000 shareholders, is considered as the second pharmaceutical holding of the country in the pharmaceutical industry.
Barkat Pharmaceutical Group Company (Public Joint Stock Company) was established with more than 20 subsidiaries in 2010 based on the analysis and foresight of Iran's pharmaceutical industry and to meet the needs of society, under the name of "Tadbir New Pharmaceutical Technologies Company". The company, as a knowledge-based economic complex, has chosen its approach to focus on health products. Barkat Pharmaceutical Group operates with 25 companies in its subsidiary, all of which are active in the drug supply chain.
The current managing director of the Barkat Pharmaceutical Group is Hamid Reza Jamshidi, who has a Ph.D. degree in Pharmacy from the University of Isfahan and a Ph.D. in Neuroscience from the University of Alberta, Canada.
One of the activities of the Barkat Pharmaceutical Group is the building of a 200-hectare pharmaceutical town. Also, "cell therapy" by producing five products for the treatment of skin and heart disease and knee arthritis, production of "peptide medications" using in the treatment of high-dose diseases such as Multiple sclerosis, blood diseases and cancer, "Research and development and processing of medicinal plants", to use domestic capacities and prevent the sale of raw materials and entry into world markets, the "Museum of Iranian-Islamic medicine" to show the role of Iranian scientists in medicine, as well as the "Solids and Semi-Solids" projects to increase the production of various pharmaceutical products, are among other activities of the Barkat Pharmaceutical Group.
Hub AI
Barkat Pharmaceutical Group AI simulator
(@Barkat Pharmaceutical Group_simulator)
Barkat Pharmaceutical Group
Barkat Pharmaceutical Group (Persian: گروه دارویی برکت, Gruh-e Darvii-ye Berekât) is an Iranian Pharmaceutical public company, which was founded in 2010, named Tadbir innovation pharmaceutical company. The company provides services through cooperation between science-based institutions and scientists based on medicine around the world. It supplies 14 percent of all the country's essential drugs through its 25 subsidiaries. The company produces 700 kinds of products in the pharmaceutical sector and offers it internally.
The Barkat Pharmaceutical Group has established as the first specialized drug and pharmaceutical research center in Iran, also it has been developed by constructing advanced pharmaceutical factories, called Barkat Pharmaceutical Town. The Barkat group complies with all common pharmaceutical standards such as the FDA, WHO, EMEA. "Cell therapy", production of "peptide medications", "research, development and processing of medicinal plants," the creation of the "Museum of Iranian-Islamic Medicine" as well as "Solids and Semi-Solids" projects are the main activities of the Group.
On 4 December 2016, the company was listed as Tehran Stock Exchange's 506th company after receiving 340 billion Rials in funding.
On 5 February 2017, 340 million shares of the Barkat Pharmaceutical Group were first Released on the Tehran Stock Exchange in the Group of Pharmaceutical Materials and Products. By this date, 50% of the company's shareholders were natural people. According to Baqerinezhad, the company's research and development deputy, 800 billion tomans is defined as investment, for the second five-year development plan of the company. Also, in order to realize the support of the private sector, a Research and Development Fund of Bold investing (VC) has been launched. It is also possible to invest over $5 billion, in full capacity, in the Barkat Pharmaceutical Town.
The Barkat Pharmaceutical Group has signed investment contracts with 30 and domestic medical and healthcare companies in the healthcare industry. So far in order to produce medicines, there are three contracts between pharmaceutical companies from Switzerland, the UK and Denmark for producing medicines. The direct investment contract of €70 million with a Danish pharmaceutical company in 2015 and a contract of $15 million with a Swiss company in 2016 were among the most important of these contracts. This holding, which has more than 500,000 shareholders, is considered as the second pharmaceutical holding of the country in the pharmaceutical industry.
Barkat Pharmaceutical Group Company (Public Joint Stock Company) was established with more than 20 subsidiaries in 2010 based on the analysis and foresight of Iran's pharmaceutical industry and to meet the needs of society, under the name of "Tadbir New Pharmaceutical Technologies Company". The company, as a knowledge-based economic complex, has chosen its approach to focus on health products. Barkat Pharmaceutical Group operates with 25 companies in its subsidiary, all of which are active in the drug supply chain.
The current managing director of the Barkat Pharmaceutical Group is Hamid Reza Jamshidi, who has a Ph.D. degree in Pharmacy from the University of Isfahan and a Ph.D. in Neuroscience from the University of Alberta, Canada.
One of the activities of the Barkat Pharmaceutical Group is the building of a 200-hectare pharmaceutical town. Also, "cell therapy" by producing five products for the treatment of skin and heart disease and knee arthritis, production of "peptide medications" using in the treatment of high-dose diseases such as Multiple sclerosis, blood diseases and cancer, "Research and development and processing of medicinal plants", to use domestic capacities and prevent the sale of raw materials and entry into world markets, the "Museum of Iranian-Islamic medicine" to show the role of Iranian scientists in medicine, as well as the "Solids and Semi-Solids" projects to increase the production of various pharmaceutical products, are among other activities of the Barkat Pharmaceutical Group.